Follow
← Back
Medicines · Interactions

Azilsartan medoxomil — interactions

Other medicines, foods and herbal products can change how Azilsartan medoxomil works. Everything on this page comes from Azilsartan medoxomil's own FDA-approved label — the same source as the main guide.

← Back to the full Azilsartan medoxomil guide

⚠ Caution: Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia. Lithium: Increases in serum lithium concentrations and lithium toxicity.

Medicines named in Azilsartan medoxomil's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Non-steroidal Anti-Inflammatory Agents,

Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy) or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.

Dual Blockade

Of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors or aliskiren is associated with increased risks of hypotension, hyperkalemia and changes in renal function (including acute renal failure) compared to monotherapy.

Section 7.3 of the label

Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.
Read the full interactions section from Azilsartan medoxomil's label

Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia. Lithium: Increases in serum lithium concentrations and lithium toxicity.

7.1 Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy) or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.

7.2 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors or aliskiren is associated with increased risks of hypotension, hyperkalemia and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on azilsartan medoxomil tablets and other agents that affect the RAS. Do not coadminister aliskiren with azilsartan medoxomil tablets in patients with diabetes. Avoid use of aliskiren with azilsartan medoxomil tablets in patients with renal impairment (GFR <60 mL/min).

7.3 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use.

Azilsartan medoxomil guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 13 May 2026) · NepalDoc medicine catalog · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Azilsartan medoxomil's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.